Emulsion containing amniotic mesenchymal stem cell cytokines and preparation method thereof
Through the extraction of amniotic mesenchymal stem cells and specific formula emulsion components, the problem of incomplete stem cell extraction in the existing technology is solved, and the moisturizing, wrinkle reduction and antioxidant effects of skin repair lotions are improved, achieving better skin repair capabilities and large-scale production.
Patent Information
- Application Number
- CN202411149673.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-26
AI Technical Summary
In the prior art, stem cell extraction is incomplete, resulting in poor moisturizing, spot-relieving, wrinkle reduction and other effects of skin repair lotions.
Using a preparation method of amniotic mesenchymal stem cell-containing cytokine emulsion, the isolation, culture, collection and concentration of amniotic mesenchymal stem cells are combined with emulsion components of specific formulas, including polyglycerol-6 disaltar Acid esters, cetyl alcohol, European ash bark extract, etc., form efficient skin repair products.
It achieves better skin moisturizing, wrinkle reduction and antioxidant effects, improves skin repair capabilities, is easy to operate and can be produced on a large scale.
Smart Images

Figure CN119015162A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, and in particular to an amniotic membrane mesenchymal stem cell cytokine emulsion and a preparation method thereof. Background Art
[0002] With the increase of age and changes in living environment, skin metabolism will cause dryness, roughness, peeling, acne marks, sunburn, acne and other scars.
[0003] At present, a large number of studies have shown that stem cells can secrete a variety of cytokines to repair tissues, such as: secreting neurotrophic factors, angiogenesis factors, hematopoietic support factors, immunomodulatory factors, anti-apoptotic factors and chemokines. Among the many stem cells, the most commonly used are mesenchymal stem cells (MSCs). They have a wide range of sources, and mesenchymal stem cells have been isolated from bone marrow, peripheral blood, placenta, fat, amniotic membrane, umbilical cord blood, umbilical cord and other tissues. Among them, peripheral blood and bone marrow mesenchymal stem cells have a long culture time and low content, and the cell proliferation and differentiation potential decreases significantly with age; amniotic membrane tissue is the only tissue in the human body that does not contain blood vessels, lymph and nerves. It can survive only with nutrition provided by amniotic fluid, has strong vitality, and is easy to obtain, rich in sources, and does not involve ethical issues. It has become a very potential and high-quality source of MSCs.
[0004] Amniotic mesenchymal stem cells are derived from amniotic tissue. They secrete a variety of cytokines, such as epidermal growth factor (EGF), which can quickly repair damaged skin, induce angiogenesis, and stimulate the division and proliferation of specific cell groups to repair tissues.
[0005] With the continuous development of biotechnology, cytokines have been applied to skin repair products, but the preparation methods of most products are too complicated to meet the large demand for skin repair products, and the preparation process is time-consuming. At present, Chinese patent CN108853001A discloses a skin lotion containing stem cell extracts and a preparation method thereof. The stem cell extract in the skin lotion is obtained by lysing and centrifuging the MSCs obtained by separation and culture of Wharton's block. Although this method is relatively simple, in fact, in addition to the cytokines that have a skin repairing effect, the stem cell extract also contains other substances, and the extraction is incomplete, resulting in poor skin repair effects such as moisturizing, lightening, and wrinkle reduction of the obtained lotion. Summary of the invention
[0006] In view of the above-mentioned deficiencies in the prior art, the purpose of the present invention is to provide an amniotic membrane mesenchymal stem cell cytokine emulsion and a preparation method thereof, aiming to solve the problem of incomplete stem cell extraction in the prior art, resulting in poor skin repair effects such as moisturizing, freckle removal and wrinkle reduction of the obtained emulsion.
[0007] In order to achieve the above object, the present invention adopts the following technical solutions: In a first aspect, a method for preparing an amniotic membrane mesenchymal stem cell cytokine emulsion is provided, the preparation method comprising the following steps: A. Preparation of amniotic membrane mesenchymal stem cell factor: amniotic membrane mesenchymal stem cell factor is obtained by separation and culture of amniotic membrane mesenchymal stem cells, subculture, supernatant collection and supernatant concentration; B. Prepare an emulsion containing amniotic membrane mesenchymal stem cell factor: take 1-3 parts of EMULIUM MELLIFERA MB (polyglyceryl-6 distearate, jojoba lipids, polyglyceryl-3 beeswax acid ester, cetyl alcohol), 0.25-1 parts of EMULCIRE 61 WL 2659 CGMB (cetyl alcohol, cetyl alcohol polyether-20, stearyl alcohol polyether-20), 1.5-6 parts of C10-C18 fatty acid glycerides, 1.5-5 parts of diethyl ethyl sebacate, 3-7 parts of caprylic / sunflower triglyceride, 0.5-2 parts of avocado butter, 2.5-7 parts of octyldodecanol myristate, and 0.5-3 parts of polymethylsilsesquioxane, stir and mix to obtain a first mixture; Mix 0.5-3 parts of Fraxinus chinensis bark extract, 2.5-8 parts of propylene glycol, and 2.5-8 parts of glycerol to obtain a second mixture; The cytokine obtained in step A is mixed evenly with the first mixture and the second mixture in a ratio of 1:1, and the mixture is allowed to stand to obtain an amniotic membrane mesenchymal stem cell factor-containing emulsion.
[0008] Furthermore, the preparation of the amniotic membrane mesenchymal stem cell factor described in step A comprises the following specific steps: Step 1: Isolation and culture of amniotic mesenchymal stem cells: Take 5×5cm of healthy human amniotic tissue 2, wash thoroughly with pH 7.2 phosphate buffer, place the amniotic membrane in physiological saline containing 0.1 million U / ml gentamicin and 2.5μg / ml amphotericin B, soak for 15-20 minutes; cut the amniotic membrane into pieces, first use a final concentration of 2.5g / L trypsin, digest at 37℃ for 20-30 minutes, and then remove the digestion solution for 800-1000r mp / min for 3-5min, discard the supernatant; a total of 2-4 times, then use DMEM / F12 culture medium to stop trypsin, use DMEM / F12 culture medium containing VDMEM:VF12=1:1 with a final concentration of 1.0g / L collagenase IV and 0.1g / L deoxyribonuclease I, digest at 37℃ for 30-60min to obtain a cell suspension; filter the cell suspension, filter the digested cells with a 200-mesh stainless steel mesh to make a single cell suspension, 800-1000rpm / min, centrifuge for 5-10min, wash 2-4 times with pH7.2 phosphate buffer PBS; discard the supernatant, and obtain amniotic mesenchymal stem cells; use 2×10 7 L -1 ∽2×10 8 L -1 Density inoculated in culture medium for cultivation; Step 2, subculture of amniotic mesenchymal stem cells: discard the culture medium of the cells to be subcultured in step 1, add trypsin with a final concentration of 2.5g / L, incubate at 37°C for 1-3min, add cell subculture medium to terminate digestion after the cells become round, shake quickly, blow the cells, aspirate the cell suspension, add physiological saline to wash, centrifuge, collect the precipitate, resuspend the precipitate with PBS buffer, and inoculate into the cell subculture medium for P 1 When the cells grow to 80%-90% of the bottom area of the bottle, continue to subculture until P 5 generation; Collection of supernatant: Collect culture P 1 -P 4 The supernatant of amniotic mesenchymal stem cells; Step 3, concentration of supernatant: The supernatant collected in step 2 is filtered sequentially with filter membranes with molecular weight cutoff of 100,000Da and 1000Da, concentrated 10-20 times, and sterilized and filtered with a 0.22μm filter membrane to obtain an amniotic membrane mesenchymal stem cell factor concentrate.
[0009] Furthermore, the culture conditions used for the amniotic mesenchymal stem cells are 37°C and 5% CO 2 saturated humidity.
[0010] Furthermore, the cell density of the inoculation in step 2 is 2×10 7 L -1 -2×10 8 L -1.
[0011] Furthermore, the complete culture medium comprises: a DMEM / F12 serum-free culture medium with a ratio of VDMEM:VF12=1:1, with a volume fraction of 15.0-15.6 g / L, containing a volume fraction of 5.0-10×10 -1 % human serum albumin, 1.0-5.5×10 -1 g / L human transferrin, 5.0-10×10 -1 g / L human insulin, 5.2-6.7×10 -4 g / L of sodium selenite.
[0012] Further, in step B, 1-3 parts of EMULIUM MELLIFERA MB (polyglyceryl-6 distearate, jojoba lipids, polyglyceryl-3 beeswax acid ester, cetyl alcohol), 0.25-1 parts of EMULCIRE 61 WL 2659 CG MB (cetyl alcohol, cetyl alcohol polyether-20, stearyl alcohol polyether-20), 1.5-6 parts of C10-C18 fatty acid glycerides, 1.5-5 parts of diethyl ethyl sebacate, 3-7 parts of caprylic / sebacate triglycerides, 0.5-2 parts of avocado tree butter, 2.5-7 parts of octyldodecanol myristate, and 0.5-3 parts of polymethylsilsesquioxane are stirred and mixed to obtain a first mixture.
[0013] Furthermore, the amniotic membrane mesenchymal stem cell factor emulsion described in step B comprises the following raw materials in parts by weight: 7-12 parts of amniotic membrane mesenchymal stem cell factor, 1-3 parts of EMULIUM MELLIFERA MB (polyglyceryl-6 distearate, jojoba lipids, polyglyceryl-3 beeswax acid ester, cetyl alcohol), EMULCIRE 61 WL 2659 CG MB (cetyl alcohol, cetyl alcohol polyether-20, steareth-20) 0.25-1 parts, C10-C18 fatty acid glycerides 1.5-6 parts, diethyl ethyl caprylate 1.5-5 parts, caprylic / capric triglyceride 3-7 parts, avocado butter 0.5-2 parts, octyldodecanol myristate 2.5-7 parts, polymethyl silsesquioxane 0.5-3 parts, European ash bark extract 0.5-3 parts, propylene glycol 2.5-8 parts, glycerin 2.5-8 parts.
[0014] In a second aspect, an application of the above-mentioned amniotic membrane mesenchymal stem cell cytokine emulsion is prepared by adding the composition into cosmetics.
[0015] Furthermore, the cosmetic is one or more of an aqueous solution, an emulsion, a spray, a cream, a mask, The technical solution adopted by the present invention has the following beneficial effects: Compared with the prior art, the advantages of the present invention are: the human amniotic mesenchymal stem cells (HAMSCs) of the present invention use serum-free culture medium, compared with mesenchymal stem cells cultured with fetal bovine serum, and have the advantages of no other animal origin, wide sources, no ethical restrictions and low immunogenicity.
[0016] The present invention provides a method for preparing an amniotic membrane mesenchymal stem cell cytokine emulsion. The amniotic membrane mesenchymal stem cells used are derived from human amniotic membrane. The emulsion produced by the method has the effects of wrinkle reduction, moisturizing, anti-oxidation and other tissue repairing effects. The operation is simple and can be mass-produced.
[0017] The present invention promotes skin metabolism, enhances the efficacy of epidermal differentiation and regeneration, promotes the rapid establishment of the skin's own "microecology" through epidermal differentiation and regeneration, and performs excellently in skin tissue repair and restoration of skin barrier function. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 Light microscopic photograph of hAMSCs cells (×40); Figure 2 Identification of the differentiation potential of hAMSCs; Figure 3 hAMSCs surface marker flow cytometry; Figure 4 Effect of stem cell exocytosis active factor hAMSCs-CM on the proliferation of keratinocytes; Figure 5 Effect of stem cell exocytotic active factor hAMSCs-CM on keratinocyte migration; Figure 6 hAMSCs-CM, an exogenous active factor secreted by stem cells, accelerates wound healing in mice and inhibits the differentiation of keratinocytes. DETAILED DESCRIPTION
[0019] In order to make the purpose, technical solution and effect of the present invention clearer and more specific, the present invention is further described in detail with reference to the accompanying drawings and examples. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0020] Example 1 A method for preparing an emulsion containing amniotic membrane mesenchymal stem cell factors; The method specifically comprises the following steps: Preparation of cytokines from amniotic mesenchymal stem cells: (1) Isolation and culture of amniotic mesenchymal stem cells: Take 5×5 cm of healthy human amniotic tissue2 , wash thoroughly with pH 7.2 phosphate buffer (PBS), place the amniotic membrane in physiological saline containing 0.1 million U / ml gentamicin and 2.5μg / ml amphotericin B, soak for 20-30 minutes; cut the amniotic membrane into pieces, first use a final concentration of 2.5g / L trypsin, digest at 37℃ for 20-30 minutes, then remove the digestion solution and centrifuge at 800-1000rmp / min for 5-10 minutes, discard the supernatant; repeat 2-3 times, then use DMEM / F12 culture medium to stop trypsin, use a final concentration of 500-1000rmp / min Digest the cells at 37°C for 30-60 min with a DMEM / F12 culture medium containing 1.0 g / L collagenase IV and 0.1 g / L deoxyribonuclease I in a ratio of 1:1. Filter the cell suspension and filter the digested cells with a 200-mesh stainless steel mesh to make a single cell suspension. Centrifuge at 800-1200 rpm / min for 5-10 min and wash 2-4 times with pH 7.2 phosphate buffer PBS. Discard the supernatant to obtain amniotic membrane mesenchymal stem cells. 7 L -1 Density inoculated in culture medium for cultivation; (2) Subculture of amniotic mesenchymal stem cells: The cells obtained in step (1) were inoculated into the culture medium and placed in an atmosphere of 37°C, saturated humidity, and 5% CO 2 , cultured in an incubator, and the medium was fully replaced every 2-3 days according to the cell growth. When the cells reached 80%-90% of the bottom area of the culture bottle, they were digested with trypsin at a final concentration of 2.5g / L, and then subcultured at a ratio of 1:2 or 1:3, and recorded as P 1 During the subculture process, the medium was replaced every 2-3 days until the adherent cells merged with each other and covered the bottom of the bottle. The above operation was repeated for subculture and recorded as P 2 The above subculture process was continued until P 5 generation.
[0021] (3) Preparation of amniotic membrane mesenchymal stem cell factor concentrate: Collect P 1 -P 5 The supernatant of amniotic mesenchymal stem cells culture was used.
[0022] (4) Concentration of the supernatant: The supernatant collected in step (3) is first filtered with a filter membrane with a molecular weight cutoff of 100,000 Da, and then the filtrate is concentrated by replacing the filter membrane with a molecular weight cutoff of 1000 Da, with the concentration multiple being 10-20 times, and the concentrate is sterilized and filtered through a 0.22 μm filter membrane to obtain an amnion-derived amnion-derived mesenchymal stem cell cytokine concentrate; The complete culture medium includes: the complete culture medium includes: 15.6 g / L of DMEM / F12 serum-free culture medium with a ratio of VDMEM:VF12=1:1, containing 8.0×10 -1 % human serum albumin, 5.0×10 -1 g / L human transferrin, 8.0×10 -1 g / L human insulin, 6.0×10 -4 g / L sodium selenite.
[0023] The cell culture medium includes: DMEM / F12 culture medium with a ratio of VDMEM:VF12=1:1.
[0024] A. Preparation of emulsion containing amniotic mesenchymal stem cell cytokines: (5) In parts by weight, 1 part of EMULIUM MELLIFERA MB, 0.25 part of EMULCIRE 61 WL 2659 CG MB, 1.5 parts of C10-C18 fatty acid glycerides, 1.5 parts of diethyl ethyl sebacate, 3 parts of caprylic / sebacate triglycerides, 0.5 part of avocado butter, 2.5 parts of octyldodecanol myristate, and 0.5 part of polymethylsilsesquioxane are stirred and mixed at 80° C. to obtain a first mixture; (6) By weight, 0.5 parts of Fraxinus fulva bark extract, 2.5 parts of propylene glycol, and 2.5 parts of glycerol were mixed to obtain a second mixture; (7) Take 7 parts by weight of the amniotic membrane mesenchymal stem cell complex factor obtained in step A, mix it evenly with the first mixture obtained in step (5) and the second mixture obtained in step (6) at room temperature at a high speed of 1000-1500 rpm / min, and let it stand for 20-30 minutes to obtain an emulsion containing amniotic membrane mesenchymal stem cell factor.
[0025] The prepared emulsion containing amniotic membrane mesenchymal stem cell cytokines includes the following raw materials in parts by weight: 7 parts of amniotic membrane mesenchymal stem cell complex factors, 1 part of EMULIUM MELLIFERA MB, 0.25 parts of EMULCIRE 61 WL2659 CG MB, 1.5 parts of C10-C18 fatty acid glycerides, 1.5 parts of diethyl ethyl sebacate, 3 parts of caprylic / sunflower triglycerides, 0.5 parts of avocado butter, 2.5 parts of octyldodecanol myristate, 0.5 parts of polymethyl silsesquioxane, 0.5 parts of European ash bark extract, 2.5 parts of propylene glycol, and 2.5 parts of glycerin.
[0026] Example 2 A method for preparing an emulsion containing amniotic membrane mesenchymal stem cell factors, the method specifically comprising the following steps: Preparation of amniotic mesenchymal stem cell complex factors: (1) Isolation and culture of amniotic mesenchymal stem cells: Take healthy human amniotic tissue, soak it in 75% ethanol for 1-3 minutes, cut the amniotic membrane into pieces, transfer it to complete culture medium for culture, and place it in a 37°C, 5% CO 2 Culture in an incubator, and subculture when the cells reach 80%-90% of the bottom area of the culture bottle. Take human amniotic membrane 5×5cm 2 , cut as much as possible, first use 2.5g / L trypsin at room temperature for 30-60min, a total of 2-4 times, then use DMEM / F12 culture medium to stop trypsin, use VDMEM:VF12=1:1 DMEM / F12 culture medium containing 1.0-2.0g / L collagenase IV and 0.1-0.2g / L deoxyribonuclease I, digest for 30-60min at 37℃ to obtain cell suspension; filter the cell suspension to make a single cell suspension; filter the digested cells with a 200-mesh stainless steel mesh to make a single cell suspension, 800-1000rpm / min, centrifuge for 5-10min, wash 2-3 times with pH7.2 phosphate buffer PBS; centrifuge again, the speed of the centrifuge is 1500-2500rpm / min, 10-20min, discard the supernatant, and obtain amniotic mesenchymal stem cells. 2×10 7 L -1 Density inoculated in culture medium for cultivation; (2) Subculture of amniotic mesenchymal stem cells: The cells obtained in step (1) were inoculated into the culture medium and placed in an atmosphere of 37°C, saturated humidity, and 5% CO 2 , cultured in an incubator, and the medium was completely replaced every 2-3 days according to the cell growth. When the cells reached 80%-90% confluence, they were digested with trypsin at a final concentration of 2.5 g / L, and then subcultured at a ratio of 1:2 or 1:3, and recorded as P 1 During the subculture process, the medium was replaced every 2-3 days until the adherent cells merged with each other and covered the bottom of the bottle. The above operation was repeated for subculture and recorded as P 2 The above subculture process was continued until P 5 generation.
[0027] (3) Preparation of amniotic mesenchymal stem cell cytokine concentrate: Collect P 1 -P 5 The supernatant of cultured amnion mesenchymal stem cells was used.
[0028] (4) Concentration of the supernatant: The supernatant collected in step (3) is first filtered through a filter membrane with a molecular weight cutoff of 100,000 Da, and then the filtrate is concentrated by replacing the filter membrane with a molecular weight cutoff of 1000 Da. The concentration multiple is 10-20 times, and the concentrate is sterilized and filtered through a 0.22 μm filter membrane to obtain an amnion mesenchymal stem cell factor concentrate; The complete culture medium includes: the complete culture medium includes: 15.0 g / L of DMEM / F12 serum-free culture medium with a ratio of VDMEM:VF12=1:1, containing 5.0×10 -1 % human serum albumin, 1.0×10 -1 g / L human transferrin, 5.0×10 -1 g / L human insulin, 5.2×10 -4 g / L sodium selenite.
[0029] The cell culture medium includes: DMEM / F12 culture medium with a ratio of VDMEM:VF12=1:1.
[0030] Preparation of emulsion containing amniotic mesenchymal stem cell cytokines: (5) In parts by weight, 1.5 parts of EMULIUM MELLIFERA MB, 0.4 parts of EMULCIRE 61 WL 2659 CG MB, 2.5 parts of C10-C18 fatty acid glycerides, 2 parts of diethyl ethyl sebacate, 4 parts of caprylic / sebacate triglycerides, 0.75 parts of avocado butter, 4 parts of octyldodecanol myristate, and 2 parts of polymethylsilsesquioxane are stirred and mixed at 80° C. to obtain a first mixture; (6) By weight, 0.75 parts of Fraxinus chinensis bark extract, 4 parts of propylene glycol, and 4 parts of glycerol were mixed to obtain a second mixture; (7) Taking 9 parts by weight of the amniotic membrane mesenchymal stem cell complex factor obtained in step A, and mixing them evenly with the first mixture obtained in step (5) and the second mixture obtained in step (6) at room temperature at a high speed of 1000-1500 rpm, and letting them stand for 30-60 minutes to obtain an emulsion containing amniotic membrane mesenchymal stem cell factors.
[0031] The prepared emulsion containing amniotic membrane mesenchymal stem cell factor includes the following raw materials in parts by weight: 9 parts of amniotic membrane mesenchymal stem cell complex factor, 1.5 parts of EMULIUM MELLIFERA MB, 0.4 parts of EMULCIRE 61 WL 2659 CG MB, 2.5 parts of C10-C18 fatty acid glycerides, 2 parts of diethyl ethyl sebacate, 4 parts of caprylic / sunflower acid triglycerides, 0.75 parts of avocado tree butter, 4 parts of octyldodecanol myristate, 2 parts of polymethylsilsesquioxane, 0.75 parts of European ash bark extract, 4 parts of propylene glycol, and 4 parts of glycerol.
[0032] Example 3 A method for preparing an emulsion containing amniotic membrane mesenchymal stem cell factors, the method specifically comprising the following steps: Preparation of amniotic mesenchymal stem cell complex factors: (1) Isolation and culture of amniotic mesenchymal stem cells: Take healthy human amniotic tissue, soak it in 75% ethanol for 1-3 minutes, cut the amniotic membrane into pieces, transfer it to complete culture medium for culture, and place it in a 37°C, 5% CO 2 Culture in an incubator, and subculture when the cells reach 80%-90% of the bottom area of the culture bottle. Take human amniotic membrane 5×5cm 2 , cut as much as possible, first use 2.5g / L trypsin at room temperature for 30-60min, 2-4 times, then use DMEM / F12 culture medium to stop trypsin, use VDMEM:VF12=1:1 DMEM / F12 culture medium containing 1.0-2.0g / L collagenase IV and 0.1-0.2g / L deoxyribonuclease I, digest at 37℃ for 30-60min to obtain cell suspension; filter the cell suspension to make a single cell suspension; filter the digested cells with a 200-mesh stainless steel mesh to make a single cell suspension, 1000-1500rpm / min, centrifuge for 5-10min, wash with pH7.2 phosphate buffer PBS 2-3 times; centrifuge again, the speed of the centrifuge is 1500-2500rpm / min, 10-20min, discard the supernatant, and obtain amniotic mesenchymal stem cells. 2×10 8 L -1 Density inoculated in culture medium for cultivation; (2) Subculture of amniotic mesenchymal stem cells: The cells obtained in step (1) were inoculated into the culture medium and placed in a 37°C, saturated humidity, 5% CO 2 , cultured in an incubator, and the medium was changed 1-2 times every 2-3 days according to the cell growth. When the cells reached 80%-90% of the bottom area of the culture bottle, they were digested with trypsin at a final concentration of 2.5g / L, and then subcultured at a ratio of 1:2 or 1:3, and recorded as P1 During the subculture process, the medium was replaced every 2-3 days until the adherent cells merged with each other and covered the bottom of the bottle. The above operation was repeated for subculture and recorded as P 2 The above subculture process was continued until P 5 generation.
[0033] (3) Preparation of amniotic membrane mesenchymal stem cell factor concentrate: Collect P 1 -P 5 The supernatant of amniotic mesenchymal stem cells culture was used.
[0034] (4) Concentration of the supernatant: The supernatant collected in step (3) is first filtered using a filter membrane with a molecular weight cutoff of 100,000 Da, and then the filtrate is concentrated by replacing the filter membrane with a molecular weight cutoff of 1000 Da. The concentration multiple is 10-20 times, and the concentrate is sterilized and filtered through a 0.22 μm filter membrane to obtain an amnion mesenchymal stem cell cytokine concentrate; The complete culture medium includes: the complete culture medium includes: 15.6 g / L of DMEM / F12 serum-free culture medium with a ratio of VDMEM:VF12=1:1, containing 1.0×10 -1 % human serum albumin, 5.5×10 -1 g / L human transferrin, 10×10 -1 g / L human insulin, 6.7×10 -4 g / L sodium selenite.
[0035] The cell culture medium includes: DMEM / F12 culture medium with a ratio of VDMEM:VF12=1:1.
[0036] Preparation of amniotic mesenchymal stem cell-containing cytokine emulsion: (5) In parts by weight, 3 parts of EMULIUM MELLIFERA MB, 1 part of EMULCIRE 61 WL 2659 CG MB, 6 parts of C10-C18 fatty acid glycerides, 5 parts of diethyl ethyl sebacate, 7 parts of caprylic / sunflower triglyceride, 2 parts of avocado butter, 7 parts of octyldodecyl myristate, and 3 parts of polymethylsilsesquioxane are stirred and mixed at 80° C. to obtain a first mixture; (6) by weight, 3 parts of Fraxinus ensifera bark extract, 8 parts of propylene glycol, and 8 parts of glycerol were stirred and mixed to obtain a second mixture; (7) Taking 12 parts by weight of the amniotic membrane mesenchymal stem cell complex factor obtained in step A, and mixing them evenly with the first mixture obtained in step (5) and the second mixture obtained in step (6) at room temperature at a high speed of 1000-1500 rpm, and letting them stand for 30-50 minutes to obtain an emulsion containing amniotic membrane mesenchymal stem cell factors.
[0037] The prepared emulsion containing amniotic membrane mesenchymal stem cell cytokines includes the following raw materials in parts by weight: 12 parts of amniotic membrane mesenchymal stem cell complex factors, 3 parts of EMULIUM MELLIFERA MB, 1 part of EMULCIRE 61 WL 2659 CG MB, 6 parts of C10-C18 fatty acid glycerides, 5 parts of diethyl ethyl sebacate, 7 parts of caprylic / sunflower triglycerides, 2 parts of avocado tree butter, 7 parts of octyldodecanol myristate, 3 parts of polymethyl silsesquioxane, 3 parts of European ash bark extract, 8 parts of propylene glycol, and 8 parts of glycerol.
[0038] Example 4 Figure 2 Identification of the differentiation potential of hAMSCs.
[0039] hAMSCs were cultured to the third generation. Human osteogenic differentiation medium was used for 3 weeks until bone particles appeared on the cell surface. The cells were fixed with 4% formaldehyde and stained with Alizarin red working solution. The cells were observed under a microscope and photographed.
[0040] The cells of the third generation were cultured in human adipose differentiation medium for about 3 weeks, and obvious round bubbles were observed under the microscope. They were fixed with 4% formaldehyde, stained with Oil Red O working solution, and observed and recorded under a microscope.
[0041] The hAMSCs were washed with PBS for 2-3 times and centrifuged to obtain cell pellets. After culturing the cell pellets with human chondrogenic medium for 3-4 weeks, the cell clusters were observed to become round. The cell clusters were fixed with 4% formaldehyde, coated, sliced with a cryostat, stained with Alcian blue working solution, and observed and recorded under a microscope.
[0042] Identification results: hAMSCs cells are long spindle-shaped and distributed like fish schools. Figure 1 hAMSCs-induced bone particles were stained with alizarin red dye, and the bone particles were dark red; the induced lipid droplets were stained with oil red O dye, and the lipid droplets were orange-red; the induced chondrocytes were sliced with a cryostat and stained with alcian blue dye. hAMSCs induction results are shown in Figure 2 , indicating that hAMSCs have multidirectional differentiation potential, which makes them have important application value in the fields of regenerative medicine and tissue engineering.
[0043] Example 5 Figure 3Detection of surface markers of hAMSCs by flow cytometry.
[0044] Identification of surface markers of hAMSCs hAMSCs were cultured to the third generation, digested with trypsin at a final concentration of 2.5 g / L to obtain a cell suspension, washed 2 to 3 times with PBS, and stained with phycoerythrin (PE)-coupled antibodies for CD73, CD45, CD31, CD105, CD44, and CD34. Cell surface markers were identified using flow cytometry.
[0045] Identification results: The identification results of hAMSCs surface markers are shown in Figure 3 Compared with the control group, CD44, CD73, and CD105 were expressed positively, while CD34, CD45, and CD31 were expressed negatively. This further indicates that they are mesenchymal stem cells and have the characteristics of mesenchymal stem cells, which is consistent with the characteristics of stem cell surface markers.
[0046] Example 6 Figure 4 Effect of stem cell exocytosis active factor hAMSCs-CM on the proliferation of keratinocytes MTS assay and cell cycle detection The MTS assay was used to analyze cell proliferation. Keratinocytes were cultured at 1.5-2.5×10 4 Cells were seeded in 96-well plates. After 12-24 hours, hAMSCs-CM was added to the corresponding wells. Every 12-24 hours, 10µl MTS was added to the wells to be tested, followed by incubation at 37°C for 2 hours, and the values at 490nm wavelength were measured using an ELISA reader.
[0047] Cell cycle was analyzed by flow cytometry (FACS). Keratinocytes were seeded in 6-well plates and cultured to 3-40% confluence, and then hAMSCs-CM was added and cultured for 2-3 days. Keratinocytes were digested into suspension cells using trypsin, resuspended in pre-cooled PBS, and resuspended in pre-cooled 70% ethanol overnight. The cells were then washed 1-2 times with pre-cooled PBS and resuspended in propidium staining solution into a single cell suspension. After incubation at room temperature for 20-30 minutes, flow cytometer analysis was performed immediately.
[0048] In order to determine the effect of hAMSCs-CM on keratinocyte proliferation, hAMSCs-CM was diluted according to the proportions, and co-cultured with keratinocytes for 3 days, respectively, into the full conditioned medium culture group, 3 / 4 conditioned medium culture group, 1 / 4 conditioned medium culture group and no conditioned medium culture group (blank control).
[0049] The MTS experimental results are as follows Figure 4As shown in A, as the concentration of hAMSCs-CM increases, the ability of conditioned medium to inhibit keratinocyte proliferation becomes stronger. Therefore, flow cytometry was used to further compare the effect of conditioned medium on keratinocyte cycle. The results showed that hAMSCs-CM has the ability to inhibit S phase when cultured for a long time, such as Figure 4 As shown in B.
[0050] Example 7 Figure 5 Effect of stem cell exocytotic active factor hAMSCs-CM on keratinocyte migration; Scratch test; The scratch test was used to analyze the effect of hAMSCs-CM on cell migration. Keratinocytes were seeded into 6-well plates. When the cell confluence reached 80-90%, a 500μm scratch was made horizontally and vertically using a 200ul sterile pipette tip. Non-adherent cells were removed by rinsing with PBS 2-3 times. Then hAMSCs-CM was added to the six-well plates respectively. Images were recorded with a digital camera at 0h, 12h, 24h, 36h and 48h, and the migration area of keratinocytes at each time point was measured using Image J software.
[0051] hAMSCs-CM was diluted according to the proportions, and co-cultured with keratinocytes for 2-3 days, respectively, into the full conditioned medium culture group, 3 / 4 conditioned medium culture group, 1 / 4 conditioned medium culture group and no conditioned medium culture group (blank control).
[0052] The results of the scratch test showed that as the concentration of hAMSCs-CM increased, the ability of the conditioned medium to promote migration was improved to a certain extent. Figure 5 A.
[0053] In order to avoid the interference of the inhibitory effect of conditioned medium on the results, we pretreated keratinocytes with mitomycin C for 1-2 hours and used the scratch test to determine the effect of hAMSCs-CM on the migration ability of keratinocytes. Representative images of the scratch test at different time points (0, 12, 24, 36 and 48 hours) are shown in Figure 5 B. The results showed that hAMSCs-CM had a stronger ability to promote migration compared with the control group. The above results were statistically calculated using image J for the migration area.
[0054] Example 8 Figure 6 Effect of stem cell exocytotic active factor hAMSCs-CM on keratinocyte migration; Six-week-old male C57 mice (20 ± 2 g) were obtained from the Experimental Animal Center of China Medical University with approval from the Ethics Committee (CMU2019235). They were provided with adequate food and water every day under standard laboratory conditions.
[0055] Mice were randomly divided into three groups (n = 4): phosphate buffered saline (PBS) control group; 5X hAMSCs-CM treatment group (conditioned medium was 5 times concentrated) and 25X hAMSCs-CM treatment group (conditioned medium was 25 times concentrated). The mice were first anesthetized by intraperitoneal injection of sodium pentobarbital (20 mg / kg.bw), the back skin was shaved with electric scissors, and the skin was disinfected with 75% alcohol disinfectant. Full-thickness skin (1 cm in diameter) with a sterile biopsy punch was excised from the designated area on the back of the mouse. PBS (50ul) or 5X hAMSCs-CM (50ul) or 25X hAMSCs-CM (50ul) was injected into the surrounding tissue of the wound at four points, and photographs were taken on days 0, 3, 6, 9, and 12 after surgery. The morphological analysis of the remaining wound was statistically analyzed using Image J software. The percentage of contraction was determined by the following formula using the assessed open surface area. Wound area (%) = (0 d wound area - wound area on a specific day) / 0 d wound area × 100%. On days 12-14, mice were anesthetized with sodium pentobarbital (30 mg / kg × body weight) by intraperitoneal injection and killed by anesthesia overdose. Skin tissue samples were collected for further histological analysis.
[0056] Histological examination; For histological observation, injured skin tissue was collected on the 14th day of the trauma model and fixed in 4% paraformaldehyde at 4°C overnight, then dehydrated in a gradient sucrose solution at 4°C for 48h, and then immersed in Opti-Mum Cutting Temperature Compound (OCT). The samples were embedded in a freezing microtome, cut into 8μm thick sections, mounted on slides, and then stained with hematoxylin-eosin (H&E). An Olympus FSX100 microscope was used for imaging.
[0057] Statistical analysis; The experimental results were expressed as mean ± standard error. The two-group comparison was performed with a two-tailed t-test, and the differences between multiple groups were verified by analysis of variance. Image J was used to analyze the image results, and the data were statistically analyzed using Graphpad prism. P < 0.05 was considered statistically significant.
[0058] No animals died during the experiment, and no obvious inflammatory response was observed in all treatment groups.
[0059] Compared with the control group, the wound area of the hAMSCs-CM treatment group was significantly reduced 3 days after modeling. The healing period of the hAMSCs-CM treatment group was significantly shortened during the experiment. There was no significant difference in the wound healing period between 5×hAMSCs-CM and 25×hAMSCs-CM. Figure 6 A.
[0060] The wound area statistics and quantification were completed by Image J software. Histological level showed that the wound healing speed of mice in the hAMSCs-CM treatment group was significantly faster than that in the control group.
[0061] H&E staining of skin sections showed that the regenerated epidermis in the hAMSCs-CM treated group was more similar to normal skin than that in the control group, with keratinocytes arranged neatly and densely. The epidermis in the control group showed obvious specific thickening, with keratinocytes arranged in a scattered manner. Figure 6 B. The above results show that hAMSCs-CM has a significant ability to promote wound healing in vivo. There is no significant difference in the ability of 5×hAMSCs-CM and 25×hAMSCs-CM to accelerate wound healing.
[0062] In summary, the present invention discloses an amniotic membrane mesenchymal stem cell cytokine emulsion and a preparation method thereof. The emulsion comprises a cytokine concentrate, propylene glycol, glycerol, polyglyceryl-6 distearate, jojoba lipids, polyglyceryl-3 beeswax acid ester, cetyl alcohol, cetyl alcohol polyether-20, stearyl alcohol polyether-20, cetyl alcohol, C10-C18 fatty acid glycerides, diethyl ethyl sebacic acid, caprylic acid / seed acid triglyceride, avocado tree fat, octyldodecanol myristate, polymethyl silsesquioxane and water, etc., and has the effects of whitening and lightening spots, reducing wrinkles and repairing skin.
[0063] Those skilled in the art will readily appreciate other embodiments of the present invention after considering the specification and practicing the schemes disclosed herein. The present invention is intended to cover any variations, uses or adaptations of the present invention that follow the general principles of the present invention and include common knowledge or customary techniques in the art that are not disclosed in this disclosure. The description and examples are to be considered exemplary only, and the true scope and spirit of the present invention are indicated by the claims.
Claims
1. A method for preparing an amniotic membrane mesenchymal stem cell cytokine emulsion, It is characterized in that The preparation method comprises the following steps: Preparation of amniotic membrane mesenchymal stem cell factor: amniotic membrane mesenchymal stem cell factor is obtained by separation and culture of amniotic membrane mesenchymal stem cells, subculture, supernatant collection and supernatant concentration; B. Prepare an emulsion containing amniotic membrane mesenchymal stem cell factor: respectively take 1-3 parts of polyglyceryl-6 distearate, jojoba lipids, polyglyceryl-3 beeswax acid ester, cetyl alcohol, 0.25-1 parts of cetyl alcohol, ceteth-20, steareth-20, 1.5-6 parts of C10-C18 fatty acid glycerides, 1.5-5 parts of diethyl ethyl sebacate, 3-7 parts of caprylic / sunflower triglyceride, 0.5-2 parts of avocado butter, 2.5-7 parts of octyldodecanol myristate, and 0.5-3 parts of polymethylsilsesquioxane, stir and mix to obtain a first mixture; Mix 0.5-3 parts of Fraxinus chinensis bark extract, 2.5-8 parts of propylene glycol, and 2.5-8 parts of glycerol to obtain a second mixture; The ratio of the first mixture to the second mixture is 2-1:
1. The cytokines obtained in step A are mixed with the first mixture and the second mixture in a ratio of 1:2-4, and allowed to stand to obtain an amniotic membrane mesenchymal stem cell factor-containing emulsion.
2. The method for preparing the amniotic membrane mesenchymal stem cell cytokine emulsion according to claim 1, It is characterized in that The preparation of the amniotic membrane mesenchymal stem cell factor described in step A is specifically carried out as follows: Step 1: Isolation and culture of amniotic mesenchymal stem cells: Take 5×5cm of healthy human amniotic tissue 2 , wash thoroughly with pH 7.2 phosphate buffer, place the amniotic membrane in physiological saline containing 0.1 million U / ml gentamicin and 2.5μg / ml amphotericin B, soak for 15-20 minutes; cut the amniotic membrane into pieces, first use a final concentration of 2.5g / L trypsin, digest at 37℃ for 20-30 minutes, and then remove the digestion solution for 800-1000r mp / min for 3-5min, discard the supernatant; a total of 2-4 times, then use DMEM / F12 culture medium to stop trypsin, use DMEM / F12 culture medium containing VDMEM:VF12=1:1 with a final concentration of 1.0g / L collagenase IV and 0.1g / L deoxyribonuclease I, digest at 37℃ for 30-60min to obtain a cell suspension; filter the cell suspension, filter the digested cells with a 200-mesh stainless steel mesh to make a single cell suspension, 800-1000rpm / min, centrifuge for 5-10min, wash 2-4 times with pH7.2 phosphate buffer PBS; discard the supernatant, and obtain amniotic mesenchymal stem cells; use 2×10 7 L -1 ∽2×10 8 L -1 Density inoculated in culture medium for cultivation; Step 2, subculture of amniotic mesenchymal stem cells: discard the culture medium of the cells to be subcultured in step 1, add trypsin with a final concentration of 2.5g / L, incubate at 37°C for 1-3min, add cell subculture medium to terminate digestion after the cells become round, shake quickly, blow the cells, aspirate the cell suspension, add physiological saline to wash, centrifuge, collect the precipitate, resuspend the precipitate with PBS buffer, and inoculate into the cell subculture medium for P 1 When the cells grow to 80%-90% of the bottom area of the bottle, continue to subculture until P 5 Generation; Collection of supernatant: Collect culture P 1 -P 4 The supernatant of amniotic mesenchymal stem cells; Step 3, concentration of supernatant: The supernatant collected in step 2 is filtered sequentially with filter membranes with molecular weight cutoff of 100,000Da and 1000Da, concentrated 10-20 times, and sterilized and filtered with a 0.22μm filter membrane to obtain an amniotic membrane mesenchymal stem cell factor concentrate.
3. The method for preparing the amniotic membrane mesenchymal stem cell cytokine emulsion according to claim 2, It is characterized in that The culture conditions of the amniotic mesenchymal stem cells are 37°C and 5% CO 2 saturated humidity.
4. The method for preparing the amniotic membrane mesenchymal stem cell cytokine emulsion according to claim 2, It is characterized in that The cell density in step 2 was 2 × 10 7 L -1 -2×10 8 L -1 .
5. The method for preparing the amniotic membrane mesenchymal stem cell cytokine emulsion according to claim 2, It is characterized in that The culture medium in step 1 is a DMEM / F12 serum-free culture medium with a ratio of VDMEM:VF12=1:1, with a volume fraction of 15.0-15.6 g / L, containing a volume fraction of 5.0-10×10 -1 % human serum albumin, 1.0-5.5×10 -1 g / L human transferrin, 5.0-10×10 -1 g / L human insulin, 5.2-6.7×10 -4 g / L of sodium selenite.
6. The method for preparing the amniotic membrane mesenchymal stem cell cytokine emulsion according to claim 1, It is characterized in that In step B, take polyglyceryl-6 distearate, jojoba lipids, polyglyceryl-3 beeswax acid ester, 1-3 parts of cetyl alcohol, cetyl alcohol, cetyl alcohol polyether-20, stearyl alcohol polyether-20, 0.25-1 parts, C10-C18 fatty acid glycerides 1.5-6 parts, diethyl ethyl sebacate 1.5-5 parts, caprylic acid / sebacate triglyceride 3-7 parts, avocado tree fruit fat 0.5-2 parts, octyldodecanol myristate 2.5-7 parts, polymethyl silsesquioxane 0.5-3 parts and stir to obtain a first mixture.
7. The method for preparing the amniotic membrane mesenchymal stem cell cytokine emulsion according to claim 1, It is characterized in that The amniotic membrane mesenchymal stem cell factor-containing emulsion described in step B includes the following raw materials in parts by weight: 7-12 parts of amniotic membrane mesenchymal stem cell factor, polyglyceryl-6 distearate, jojoba lipids, polyglyceryl-3 beeswax acid ester, 1-3 parts of cetyl alcohol, 0.25-1 parts of cetyl alcohol, cetyl alcohol polyether-20, stearyl alcohol polyether-20, 1.5-6 parts of C10-C18 fatty acid glycerides, 1.5-5 parts of diethyl ethyl sebacate, 3-7 parts of caprylic / sunflower triglyceride, 0.5-2 parts of avocado tree butter, 2.5-7 parts of octyldodecanol myristate, 0.5-3 parts of polymethyl silsesquioxane, 0.5-3 parts of European ash bark extract, 2.5-8 parts of propylene glycol, and 2.5-8 parts of glycerol.
8. Use of the emulsion obtained by the preparation method according to claim 1 in the preparation of cosmetics.
9. The use according to claim 8, It is characterized in that The cosmetics are one or more of aqueous solutions, emulsions, sprays, creams, and facial masks.
Citation Information
Patent Citations
Skin repair solution containing stem cell extract and preparation method thereof
CN108853001A
